HCC
SLXP

Hirtle Callaghan & Co’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Hirtle Callaghan & Co’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,000
Closed -$230K – 481
2014
Q4 		$230K Buy
+2,000
New +$242K 0.05% 181

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hirtle Callaghan & Co's SLXP Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 2,000 shares — an estimated $230K sold.

Hirtle Callaghan & Co first reported a position in SLXP in Q4 2014 and held it in 1 quarter. The position peaked at $230K in Q4 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 2,000 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $230K.
  • Hirtle Callaghan & Co first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2014 and held it in 1 quarter.
  • Hirtle Callaghan & Co's SALIX PHARMACEUTICALS LTD DEL position peaked at $230K in Q4 2014.
  • 298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.